Tyra Biosciences (TYRA) Current Assets (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Current Assets came in at $394.6 million in Q1 2026, up 21.58% YoY from $324.6 million in Q1 2025, and up 48.66% on a QoQ basis from $265.4 million in Q4 2025.
Tyra Biosciences (TYRA) Current Assets (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Current Assets data on file, last reported at $394.6 million in Q1 2026.
- Quarterly Current Assets rose 21.58% year-over-year to $394.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $394.6 million (up 21.58% YoY) and the FY2025 annual result came in at $265.4 million, down 23.6% from the prior year.
- Current Assets advanced to $394.6 million in Q1 2026, from $265.4 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $394.6 million in Q1 2026 to a low of $211.7 million in Q4 2023.
- A 5-year average of $298.3 million and a median of $281.2 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets jumped 64.15% — and 2025, when it dropped 23.6%.
- Tracing TYRA's Current Assets over 5 years: stood at $257.3 million in 2022, then fell by 17.73% to $211.7 million in 2023, then jumped by 64.15% to $347.5 million in 2024, then slipped by 23.6% to $265.4 million in 2025, then soared by 48.66% to $394.6 million in 2026.
- The last three Current Assets figures came in at $394.6 million (Q1 2026), $265.4 million (Q4 2025), and $281.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | 366.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 366.97 Mn |
| Mar 31, 2026 | 394.61 Mn |
| Dec 31, 2025 | 265.45 Mn |
| Sep 30, 2025 | 281.22 Mn |
| Jun 30, 2025 | 302.16 Mn |
| Mar 31, 2025 | 324.57 Mn |
| Dec 31, 2024 | 347.46 Mn |
| Sep 30, 2024 | 365.61 Mn |
| Jun 30, 2024 | 378.57 Mn |
| Mar 31, 2024 | 390.78 Mn |
| Dec 31, 2023 | 211.67 Mn |
| Sep 30, 2023 | 224.63 Mn |
| Jun 30, 2023 | 240.75 Mn |
| Mar 31, 2023 | 246.71 Mn |
| Dec 31, 2022 | 257.29 Mn |
| Sep 30, 2022 | 267.47 Mn |
| Jun 30, 2022 | 277.30 Mn |
| Mar 31, 2022 | 294.03 Mn |
| Dec 31, 2021 | 304.06 Mn |
| Sep 30, 2021 | 313.50 Mn |